OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins
Jan 12 2021
OXGENE™, a biotechnology company offering integrated discovery and manufacturing technologies to the cell and gene therapy industry, announces the introduction of its self-labelling integral membrane (SLIM™) protein discovery system.
The novel method allows for the identification of antibodies against membrane proteins in their native configuration in mammalian cells, which could catalyse the discovery of new candidates for antibody-based therapies.
In SLIM display, a target membrane protein and a library of potential binders are expressed in the same mammalian cells. These then progress through multiple rounds of enrichment and purification to obtain a single clone expressing a single-chain variable fragment that can bind the target antigen.